Difference between revisions of "Malignant solid neoplasm, EGFR-mutated"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) |
Warner-admin (talk | contribs) m (Text replacement - "http://ascopubs.org" to "https://ascopubs.org") |
||
Line 18: | Line 18: | ||
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]] | !style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
|- | |- | ||
− | |[ | + | |[https://ascopubs.org/doi/full/10.1200/JCO.2017.75.3780 Hainsworth et al. 2018 (MyPathway)] |
|style="background-color:#ffffbe"|Phase IIa, <20 pts in this arm | |style="background-color:#ffffbe"|Phase IIa, <20 pts in this arm | ||
|- | |- | ||
Line 30: | Line 30: | ||
===References=== | ===References=== | ||
− | # '''MyPathway:''' Hainsworth JD, Meric-Bernstam F, Swanton C, Hurwitz H, Spigel DR, Sweeney C, Burris H, Bose R, Yoo B, Stein A, Beattie M, Kurzrock R. Targeted therapy for advanced solid tumors on the basis of molecular profiles: results from MyPathway, an open-label, phase IIa multiple basket study. J Clin Oncol. 2018 Feb 20;36(6):536-542. Epub 2018 Jan 10. [ | + | # '''MyPathway:''' Hainsworth JD, Meric-Bernstam F, Swanton C, Hurwitz H, Spigel DR, Sweeney C, Burris H, Bose R, Yoo B, Stein A, Beattie M, Kurzrock R. Targeted therapy for advanced solid tumors on the basis of molecular profiles: results from MyPathway, an open-label, phase IIa multiple basket study. J Clin Oncol. 2018 Feb 20;36(6):536-542. Epub 2018 Jan 10. [https://ascopubs.org/doi/full/10.1200/JCO.2017.75.3780 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/29320312 PubMed] |
[[Category:EGFR regimens]] | [[Category:EGFR regimens]] | ||
[[Category:Biomarker-specific pages]] | [[Category:Biomarker-specific pages]] | ||
[[Category:Site-agnostic regimens]] | [[Category:Site-agnostic regimens]] |
Revision as of 15:07, 23 June 2019
1 regimens on this page
1 variants on this page
|
Note: this is a new type of page for HemOnc.org, as most other regimen pages are tissue-specific. We will collect published information from basket trials on these pages, as well as regimens that are FDA approved.
All lines of therapy
Erlotinib monotherapy
Regimen
Study | Evidence |
---|---|
Hainsworth et al. 2018 (MyPathway) | Phase IIa, <20 pts in this arm |
Eligibility criteria
- EGFR nonsynonymous exon 18 or exon 21 mutations, or exon 19 deletions
Chemotherapy
- Erlotinib (Tarceva) 150 mg PO once per day
Continued until progression or intolerance
References
- MyPathway: Hainsworth JD, Meric-Bernstam F, Swanton C, Hurwitz H, Spigel DR, Sweeney C, Burris H, Bose R, Yoo B, Stein A, Beattie M, Kurzrock R. Targeted therapy for advanced solid tumors on the basis of molecular profiles: results from MyPathway, an open-label, phase IIa multiple basket study. J Clin Oncol. 2018 Feb 20;36(6):536-542. Epub 2018 Jan 10. link to original article contains verified protocol PubMed